Registration 333-297487
- Gross proceeds
- 81250000.0
- Net proceeds
- 75562500.0
- Deal price
- 13.0
- Shares
- 6250000
- Offering price
- $13.00
- Ticker
- VOGX
Company research
Vogenx, Inc.
CIK 1903784Updated Sep 24, 2026
Filing activity
Latest filing
14 filings on record · 8-K, 10-Q, S-8, 424B4, EFFECT, 3.
About the company
We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, and towards regulatory approval.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
10-Q filing
Other Events
Items 8.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Items 5.03, 9.01
S-8 filing
Show 5 more recent filings
Offerings
Filing attachments
vogenxex99-1.htm · 8-K · 2026-09-22
Exhibit 99.1 VOGENX, INC. 3901 Barrett Drive, Suite 300 | Raleigh, North Carolina 27609 | Nasdaq: VOGX FOR IMMEDIATE RELEASE Vogenx Appoints Ken Toombs to Board of Directors Former Chief Executive Officer of PA Consulting brings three decades of global professional services and life sciences leadership experience Appointment broadens independent oversight as the Company scales operations following its August 2026 initial public offering RALEIGH, N.C., September 22, 2026 - Vogenx, Inc. (Na…
Read attachment ↗